Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
1.395
-0.155 (-10.00%)
Mar 31, 2025, 10:55 AM EDT - Market open
Cabaletta Bio Employees
As of December 31, 2023, Cabaletta Bio had 103 total employees, including 101 full-time and 2 part-time employees. The number of employees increased by 43 or 71.67% compared to the previous year.
Employees
103
Change (1Y)
43
Growth (1Y)
71.67%
Revenue / Employee
n/a
Profits / Employee
-$1,124,893
Market Cap
68.18M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 103 | 43 | 71.67% |
Dec 31, 2022 | 60 | 6 | 11.11% |
Dec 31, 2021 | 54 | 20 | 58.82% |
Dec 31, 2020 | 34 | 12 | 54.55% |
Dec 31, 2019 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CABA News
- 12 days ago - Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire
- 4 weeks ago - Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - GlobeNewsWire
- 5 weeks ago - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - GlobeNewsWire
- 6 weeks ago - Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February - GlobeNewsWire
- 2 months ago - Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - Cabaletta Bio: Finding Optimism In Dire Straits - Seeking Alpha
- 5 months ago - Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha